17432-95-0

Basic information

• Product Name: 5-isopropyluracil
• Synonyms: 5-Isopropyluracil; NSC 149002; 2,4(1H,3H)-Pyrimidinedione, 5-(1-methylethyl)-; 5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione
• CAS NO: 17432-95-0
• Molecular Formula: C₇H₁₀N₂O₂
• Molecular Weight: 154.1665
• Mol File: 17432-95-0.mol

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.142g/cm³
• Refractive Index: 1.487
• CAS DataBase Reference: 5-isopropyluracil(CAS DataBase Reference)
• NIST Chemistry Reference: 5-isopropyluracil(17432-95-0)
• EPA Substance Registry System: 5-isopropyluracil(17432-95-0)

Safety Data

• Hazardous Substances Data: 17432-95-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H10N2O2/c1-4(2)5-3-8-7(11)9-6(5)10/h3-4H,1-2H3,(H2,8,9,10,11)

Upstream product

• 7391-69-7 5-isopropylbarbituric acid 
• 18718-34-8 5-isopropyl-2-thiouracil 
• 96796-80-4 5-isopropyl-6-chloro-2,4-pyrimidinedione 
• 556-24-1 methyl 3-methylbutanoate 
• 108-64-5 Ethyl isovalerate 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 175470-85-6 1-((2R,4S,5R)-4-Benzyloxy-5-benzyloxymethyl-tetrahydro-thiophen-2-yl)-5-isopropyl-1H-pyrimidine-2,4-dione 
• 51223-64-4 C₃₃H₃₀N₂O₉ 
• 172255-86-6 1-[(2-hydroxyethoxy)methyl]-5-isopropyl-6-(phenylselenenyl)-uracil 
• 172255-87-7 1-[(2-hydroxyethoxy)methyl]-5-isopropyl-6-[(3-methylphenyl)-selenenyl]uracil 
• 172255-88-8 6-[(3,5-dimethylphenyl)selenenyl]-1-[(2-hydroxyethoxy)methyl]-5-isopropyluracil 
• 1026536-28-6 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-5-isopropyl-6-phenylselanyl-1H-pyrimidine-2,4-dione 
• 1026694-92-7 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-5-isopropyl-6-m-tolylselanyl-1H-pyrimidine-2,4-dione 
• 1026863-23-9 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-6-(3,5-dimethyl-phenylselanyl)-5-isopropyl-1H-pyrimidine-2,4-dione 
• 60136-25-6 2'-deoxy-β-D-ribofuranoside of 5-i-propyluracil 
• 76540-23-3 2'-deoxy-3',5'-di-O-(p-tolyl)-β-D-ribofuranoside of 5-i-propyluracil 
• 76549-87-6 2'-deoxy-3',5'-di-O-(p-tolyl)-α-D-ribofuranoside of 5-i-propyluracil 
• 99097-07-1 1-(3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl)-5-isopropyluracil 
• 1352571-33-5 2-chloro-5-isopropyl-4-(4-methoxybenzyloxy)pyrimidine 
• 1352570-43-4 2-(3-isopropoxy-5-(4-(methylsulfonyl)phenoxy)phenyl)-5-isopropylpyrimidin-4(3H)-one 

Relevant articles and documents

NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto． (I), (Ia)

MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX

Monocyclic pyrimidine and pyridine compounds having a benzyl amine substituent at the 4 position and a 5:6 bicyclic heteroaryl substituent at the 2 position of the pyrimidine or pyridine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

Method for producing 5-isopropyluracil

A method for producing 5-isopropyluracil at a high yield in a short time, wherein N-(2-cyano-3-methylbutanoyl)urea is reduced in a 10-15% aqueous sulfuric acid solution in the presence of palladium carbon at 30-45° C., heated for ring closure reaction and added to a 50-70% aqueous sulfuric acid solution to give 5-isopropyluracil having a high purity.

PYRIMIDINEDIONE, PYRIMIDINETRIONE, TRIAZINEDIONE AND TETRAHYDROQUINAZOLINEDIONE DERIVATIVES AS ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS

Compounds of Formula I: STR1 where R 5 is a group selected from Formulae (a), (b), (c) and (d): STR2 and the pharmaceutically acceptable salts and N-oxides thereof, are α 1-adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.

Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists

The present invention relates to novel α1-adrenoceptor antagonists of the formula I*(formula 01)* in which: R1 is acetylamino, amino, cyano, trifluoroacetylamino, halo, hydro, hydroxy, nitro, methylsulfonylamino, 2-propynyloxy, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C3-6)cycloalkyl(C1-4)alkyloxy and (C1-4)alkylthio (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, aryl(C1-4)alkyl, heteroaryl, heteroaryl(C1-4)alkyl, aryloxy, aryl(C1-4)alkyloxy, heteroaryloxy and heteroaryl(C1-4)alkyloxy (which aryl and heteroaryl are optionally further substituted with one to two radicals independently selected from halo and cyano); R2 is cyano, halo, hydro, hydroxy or a group selected from (C1-6)alkyl and (C1-6)alkyloxy (which group is optionally further substituted with one to three halogen atoms);R3 and R4 are both hydro or methyl or together are ethylene; and R5 is a group selected from Formulae (a), (b), (c) and (d):*(formula 02)* in which: X is C(O), CH2 or CH(OH); Y is CH2 or CH(OH); Z is N or C(R9), wherein R9 is hydro, (C1-6)alkyl or hydroxy; R6 is hydro, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl); R7 is (C1-6)alkanoyl, carbamoyl, cyano, di(C1-6)alkylamino, halo, hydro, hydroxy, hydroxyiminomethyl, (C1-6)alkylsulfonyl, (C1-6)alkylthio, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl,(C1-6)alkyloxy and (C1-6)alkyloxy(C1-4)alkyl (which group is optionally further substituted with one to three radicals selected from halo, hydroxy or (C1-6)alkyloxy) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl) or R7 and R9 together are tetramethylene; and each R8 is independently hydro, hydroxy, methyl or ethyl; and the pharmaceutically acceptable salts and N-oxides thereof.

The synthesis of some 5-substituted and 5,6-disubstituted 2'- deoxyuridines

5-Alkyl(cycloalkyl)-2'-deoxyuridines VIa-VIf were synthesised in high yields by condensation of the corresponding silylated bases with 2-deoxy- 3,5-di-O-p-toluoyl-D-erythro-pentosyl chloride in chloroform and subsequent deblocking with sodium methoxide in

Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships

In order to study structure-activity relationships between antiherpetic activity and the size of the C-5 alkyl substituents of 2'-fluoro-ara-U derivatives, six new nucleosides (1c-h) were synthesized. The 5-allyl analogue 1c was prepared by a Pd(II)-catal